



#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert J. Peach, et al. **Examiner:** Not Yet Known
Serial No.: 09/865,321 **Group Art Unit:** 1646
Filed: May 23, 2001 **Docket No.:** 30436.57USU1
Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 7, 2002.

By: Tracy Truick

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b)(3))

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUN 19 2002

Dear Sir:

TECH CENTER 1600/2900

This Supplemental Information Disclosure Statement is being filed herewith as a supplement to Applicant's June 19, 2001, Information Disclosure Statement which was submitted under 37 C.F.R. §1.97 (b)(3) before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 139-170 as set forth in the Form 1449 are included herewith.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Lakkis, Fadi G., et al., "Blocking the CD28-B7 T Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4¹," *The Journal of Immunology*, 1997, 158:2443-2448. **(Exhibit 139)**
- Pearson, Thomas C., et al., "ANALYSIS OF THE B7 COSTIMULATORY PATHWAY IN ALLOGRAFT REJECTION¹," *Transplantation*, 1997, 63:1463-1469. **(Exhibit 140)**
- Pearson, Thomas C., et al., "TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig¹," *Transplantation*, 1994, 57:1701-1706. **(Exhibit 141)**

- Pearson, Thomas C., et al., "TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig¹," *Transplantation*, 1994, 57:1701-1706. **(Exhibit 141)**
- Alexander, Diane Z., "ANALYSIS OF A FUNCTIONAL ROLE FOR CHIMERISM IN CTLA4-Ig PLUS BONE MARROW-TREATED CARDIAC ALLOGRAFT RECIPIENTS," *Transplantation*, 1994, 91:416-418. **(Exhibit 142)**
- Larsen, Christian P., et al., "CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOFRAFT REJECTION" *Transplantation*, 1996, 61:4-9. **(Exhibit 143)**
- Pearson, Thomas C., et al., "CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESPONSIVENESS IN THE MURINE MODEL", *Transplantation*, 1996, 61:997-1004. **(Exhibit 144)**
- Weber, C.J., et al., "CTLA4-Ig Prolongs Survival of Microencapsulated Rabbit Islet Xenografts in Spontaneously Diabetic Nod Mice," *Transplantation Proceedings*, 1996, 28:821-823. **(Exhibit 145)**
- Alexander, D.Z., et al., "Analysis of effector mechanisms in murine cardiac allograft rejection," *Transplantation Immunology*, 1996, 4:46-48. **(Exhibit 146)**
- Larsen, Christian P., et al., "Long-Term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," *Nature*, 1996, 381:434-438. **(Exhibit 147)**
- Elwood, Eric T., et al., "Microchimerism and rejection in clinical transplantation," *The Lancet*, 1997, 349:1358-1360. **(Exhibit 148)**
- Larsen, Christian P., and Thomas C. Pearson., "The CD40 pathway in allograft rejection, acceptance, and tolerance," *Transplantation*, 1997, 9:641-647. **(Exhibit 149)**
- Konieczny, Bogumila T., et al., "IFN- γ Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways¹," *The Journal of Immunology*, 1998, 160:2059-2064. **(Exhibit 150)**
- Elwood, Eric T., et al., "PROLONGED ACCEPTANCE OF CONCORDANT AND DISCORDANT XENOGRAFTS WITH COMBINED CD40 AND CD28 PATHWAY BLOCKADE¹," *Transplantation*, 1998, 65:1422-1428. **(Exhibit 151)**

- Niimi, Masanori, et al., "The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness in Vivo¹," *The Journal of Immunology*, 1998,161:5331-5337. **(Exhibit 152)**
- Whitmire, Jason K., et al., "CD40-CD40 Ligand Costimulation Is Required for Generating Antiviral CD4 T Cell Responses But is Dispensable for CD8 T Cell Responses¹," *The Journal of Immunology*, 1999,163:3194-3201. **(Exhibit 153)**
- Bingaman, Adam W., et al., "Vigorous Allograft Rejection in the Absence of Danger¹," *Journal of Immunology*, 2000,164:3065-3071. **(Exhibit 154)**
- Bingaman, Adam W., et al., "TRANSPLANTATION OF THE BONE MARROW MICROENVIRONMENT LEADS TO HEMATOPOIETIC CHIMERISM WITHOUT CYTOREDUCTIVE CONDITIONING," *Transplantation*, 2000, 69:2491-2496. **(Exhibit 155)**
- Durham, Megan M., et al., "Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cyto-reductive Conditioning¹," *Cutting Edge*, 2000,165:1-4. **(Exhibit 156)**
- Williams, Matthew A., et al., "Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts¹," *The Journal of Immunology*, 2000, 165: 6549-6857. **(Exhibit 157)**
- Bingaman, Adam W., et al., "The role of CD40L in T cell-dependent nitric oxide production by murine macrophages," *Transplant Immunology*, 2000, 8:195-202. **(Exhibit 158)**
- Adams, Andrew B., et al., "Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression¹," *The Journal of Immunology*, 2001, 167:1103-1111. **(Exhibit 159)**
- Meng, L., "Blockade of the CD40 Pathway Fails to Prevent CD8 T Cell-Mediated Intestinal Allograft Rejection," *Transplantation Proceedings*, 2001, 33:418-420. **(Exhibit 160)**

- Guo, Zhong., et al., "CD8 T CELL-MEDIATED REJECTION OF INTESTINAL ALLOGRAFTS IS RESISTANT TO INHIBITION OF THE CD40/CD154 COSTIMULATORY PATHWAY," *Transplantation*, 2001, 71:1351-1354. **(Exhibit 161)**
- Ha, Jongwon., et al., "Aggressive skin allograft rejection in CD28^{-/-} mice independent of the CD40/CD40L costimulatory pathway," *Transplant Immunology*, 2001, 9:13-17. **(Exhibit 162)**
- Bingaman, Adam W., et al., "ANALYSIS OF THE CD40 AND CD28 PATHWAYS ON ALLOIMMUNE RESPONSES BY CD4⁺ T CELLS IN VIVO¹," *Transplantation*, 2001, 72:1286-1292. **(Exhibit 163)**
- Adams, Andrew B., et al., "Calcineurin Inhibitor- Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates," *Diabetes*, 2002, 51:265-270. **(Exhibit 164)**
- Whelchel, JD., et al. "Evolving Strategies in immunosuppressive Therapy: The Emory Experience," *Clinical Transplants*, 1996, 20:249-255 **(Exhibit 165)**
- Ritchie, SC., et al., "Regulation of Immunostimulatory function and B7 molecule expression on murine dendritic cells," *Journal of Cellular Biochemistry*, 1995, 21A:C1-215 **(Exhibit 166)**
- Alexander, DZ., et al., "Analysis of the mechanisms of CTLA4-Ig plus bone marrow induced transplantation tolerance," *Journal of Cellular Biochemistry*, 1995, 21A:C1-301 **(Exhibit 167)**
- Alexander, DZ., et al., "CTLA4-Ig induced transplantation tolerance: analysis of donor cell chimerism," *Surgical Forum*, 1994, 45:402-403 **(Exhibit 168)**
- Pearson, TC., et al., "CTLA4-Ig plus bone marrow induces transplantation tolerance in the murine model," *Journal of Cellular Biochemistry*, 1995, 21A:C1-327 **(Exhibit 169)**
- Lakkis, FG., et al., "CTLA4Ig induces long-term cardiac allograft survival in the absence of interleukin-4," *Journal of the American Society of Nephrology*, 1996, 7:A3204 **(Exhibit 170)**

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Attorney for Applicants
Mandel & Adriano
35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801
Customer No. 26,941

c:\trt\30436(bms)\57usu1\file wrapper\ids\supplcom\mids4.doc



10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert J. Peach, et al.
Serial No.: 09/865,321
Filed: May 23, 2001
Docket: 30436.57USU1
Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on June 7, 2002.

By: 
Name: Tracy Truick

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
June 7, 2002

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

JUN 19 2002

Sir:

TECH CENTER 1600/2900


We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 139-170
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801

By: 

Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA
Customer No. 26,941




FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
RECEIVED JUN 19 2002 TECH CENTER 1600/2000			Lakkis, Fadi G., et al., "Blocking the CD28-B7 T Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4 ¹ ," <i>The Journal of Immunology</i> , 1997, 158:2443-2448. (Exhibit 139)			
			Pearson, Thomas C., et al., "ANALYSIS OF THE B7 COSTIMULATORY PATHWAY IN ALLOGRAFT REJECTION ¹ ," <i>Transplantation</i> , 1997, 63:1463-1469. (Exhibit 140)			
			Pearson, Thomas C., et al., "TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-Ig ¹ ," <i>Transplantation</i> , 1994, 57:1701-1706. (Exhibit 141)			
			Alexander, Diane Z., "ANALYSIS OF A FUNCTIONAL ROLE FOR CHIMERISM IN CTLA4-Ig PLUS BONE MARROW-TREATED CARDIAC ALLOGRAFT RECIPIENTS," <i>Transplantation</i> , 1994, 91:416-418. (Exhibit 142)			
			Larsen, Christian P., et al., "CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOFRAFT REJECTION" <i>Transplantation</i> , 1996, 61:4-9. (Exhibit 143)			
			Pearson, Thomas C., et al., "CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESONSIVENESS IN THE MURINE MODEL", <i>Transplantation</i> , 1996, 61:997-1004. (Exhibit 144)			
			Weber, C.J., et al., "CTLA4-Ig Prolongs Survival of Microencapsulated Rabbit Islet Xenografts in Spontaneously Diabetic Nod Mice," <i>Transplantation Proceedings</i> , 1996, 28:821-823. (Exhibit 145)			
			Alexander, D.Z., et al., "Analysis of effector mechanisms in murine cardiac allograft rejection," <i>Transplantation Immunology</i> , 1996, 4:46-48. (Exhibit 146)			
			Larsen, Christian P., et al., "Long-Term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways," <i>Nature</i> , 1996, 381:434-438. (Exhibit 147)			
			Elwood, Eric T., et al., "Microchimerism and rejection in clinical transplantation," <i>The Lancet</i> , 1997, 349:1358-1360. (Exhibit 148)			
		Larsen, Christian P., and Thomas C. Pearson., "The CD40 pathway in allograft rejection, acceptance, and tolerance," <i>Transplantation</i> , 1997, 9:641-647. (Exhibit 149)				
		Konieczny, Bogumila T., et al., "IFN- γ Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Costimulation Pathways ¹ ," <i>The Journal of Immunology</i> , 1998, 160:2059-2064. (Exhibit 150)				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Elwood, Eric T., et al., "PROLONGED ACCEPTANCE OF CONCORDANT AND DISCORDANT XENOGRAPHS WITH COMBINED CD40 AND CD28 PATHWAY BLOCKADE ¹ ," <i>Transplantation</i> , 1998,65:1422-1428. (Exhibit 151)
		Niimi, Masanori, et al., "The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness in Vivo ¹ ," <i>The Journal of Immunology</i> , 1998,161:5331-5337. (Exhibit 152)
RECEIVED JUN 19 2002 TECH CENTER 1640/2900		Whitmire, Jason K., et al., "CD40-CD40 Ligand Costimulation Is Required for Generating Antiviral CD4 T Cell Responses But is Dispensable for CD8 T Cell Responses ¹ ," <i>The Journal of Immunology</i> , 1999,163:3194-3201. (Exhibit 153)
		Bingaman, Adam W., et al., "Vigorous Allograft Rejection in the Absence of Danger ¹ ," <i>Journal of Immunology</i> , 2000,164:3065-3071. (Exhibit 154)
		Bingaman, Adam W., et al., "TRANSPLANTATION OF THE BONE MARROW MICROENVIRONMENT LEADS TO HEMATOPOIETIC CHIMERISM WITHOUT CYTOREDUCTIVE CONDITIONING," <i>Transplantation</i> , 2000, 69:2491-2496. (Exhibit 155)
		Durham, Megan M., et al., "Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoinductive Conditioning ¹ ," <i>Cutting Edge</i> , 2000,165:1-4. (Exhibit 156)
		Williams, Matthew A., et al., "Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts ¹ ," <i>The Journal of Immunology</i> , 2000, 165: 6549-6857. (Exhibit 157)
		Bingaman, Adam W., et al., "The role of CD40L in T cell-dependent nitric oxide production by murine macrophages," <i>Transplant Immunology</i> , 2000, 8:195-202. (Exhibit 158)
		Adams, Andrew B., et al., "Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression ¹ ," <i>The Journal of Immunology</i> , 2001, 167:1103-1111. (Exhibit 159)
		Meng, L., "Blockade of the CD40 Pathway Fails to Prevent CD8 T Cell-Mediated Intestinal Allograft Rejection," <i>Transplantation Proceedings</i> , 2001, 33:418-420. (Exhibit 160)
		Guo, Zhong., et al., "CD8 T CELL-MEDIATED REJECTION OF INTESTINAL ALLOGRAFTS IS RESISTANT TO INHIBITION OF THE CD40/CD154 COSTIMULATORY PATHWAY," <i>Transplantation</i> , 2001, 71:1351-1354. (Exhibit 161)
		Ha, Jongwon., et al., "Aggressive skin allograft rejection in CD28 ^{-/-} mice independent of the CD40/CD40L costimulatory pathway," <i>Transplant Immunology</i> , 2001, 9:13-17. (Exhibit 162)
		Bingaman, Adam W., et al., "ANALYSIS OF THE CD40 AND CD28 PATHWAYS ON ALLOIMMUNE RESPONSES BY CD4 ⁺ T CELLS IN VIVO ¹ ," <i>Transplantation</i> , 2001, 72:1286-1292. (Exhibit 163)
		Adams, Andrew B., et al., "Calcineurin Inhibitor- Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates," <i>Diabetes</i> , 2002, 51:265-270. (Exhibit 164)
		Whelchel, JD., et al. "Evolving Strategies in immunosuppressive Therapy: The Emory Experience," <i>Clinical Transplants</i> , 1996, 20:249-255 (Exhibit 165)
		Ritichie, SC., et al., "Regulation of Immunostimulatory function and B7 molecule expression on murine dendritic cells," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-215 (Exhibit 166)
		Alexander, DZ., et al., "Analysis of the mechanisms of CTLA4-Ig plus bone marrow induced transplantation tolerance," <i>Journal of Cellular Biochemistry</i> , 1995, 21A:C1-301 (Exhibit 167)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

Docket Number

30436.57USU1

Application Number

09/865.321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Alexander, DZ., et al., "CTLA4-Ig induced transplantation tolerance: analysis of donor cell chimerism," *Surgical Forum*, 1994, 45:402-403 (**Exhibit 168**)

Pearson, TC., et al., "CTLA4-Ig plus bone marrow induces transplantation tolerance in the murine model," *Journal of Cellular Biochemistry*, 1995, 21A:C1-327 (**Exhibit 169**)

Lakkis, FG., et al., "CTLA4Ig induces long-term cardiac allograft survival in the absence of interleukin-4," *Journal of the American Society of Nephrology*, 1996, 7:A3204 (**Exhibit 170**)

RECEIVED

JUN 19 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE